Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis

Clinical Therapeutics
Michael IskedjianA Lane Ilersich

Abstract

Rates of patient adherence (compliance) to pharmacotherapy range from <5% to >90%. Negative determinants include multiple daily dosing (MDD), chronic duration, and asymptomatic disease. Reports suggest that once-daily (QD) dosing may improve adherence, but their findings are inconclusive. The purpose of this study was to compare the rates of adherence with QD, twice-daily (BID), and MDD antihypertensive drug regimens. MEDLINE, Embase, and International Pharmaceutical Abstracts databases were searched to identify comparative trials of patient adherence to antihypertensive medication in solid, oral formulations. Data were combined using a random-effects meta-analytic model. Eight studies involving a total of 11,485 observations were included (1,830 for QD dosing, 4405 for BID dosing, 4147 for dosing >2 times daily [>BID], and 9655 for MDD), in which the primary objective was to assess adherence. The average adherence rate for QD dosing (91.4%, SD = 2.2%) was significantly higher (Z = 4.46, P < 0.001) than for MDD (83.2%, SD = 3.5%). This rate was also significantly higher (Z = 2.22, P = 0.026) than for BID dosing (92.7% [SD = 2.3%] vs 87.1% [SD = 2.9%]). The difference in adherence rates between BID dosing (90.8%, SD = 4.7%) and ...Continue Reading

References

May 1, 1979·Archives of Internal Medicine·P RuddG J Bostwick
Aug 1, 1991·The Gerontologist·V O LeirerG M Pariante
Sep 1, 1990·Archives of Internal Medicine·S A EisenT R Przybeck
Aug 1, 1987·Annals of Internal Medicine·K A L'AbbéK O'Rourke
Sep 1, 1987·Journal of General Internal Medicine·S A EisenC A Windham
Oct 1, 1980·American Journal of Public Health·J C HersheyM J Reichgott
May 1, 1994·Current Opinion in Nephrology and Hypertension·W J Elliott
Aug 23, 1993·Archives of Internal Medicine·R I Horwitz, S M Horwitz

❮ Previous
Next ❯

Citations

Mar 3, 2006·Advances in Therapy·Albert I WertheimerRichard A Levy
Apr 21, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Peter Oberender, Jürgen Zerth
Jun 2, 2009·Wiener medizinische Wochenschrift·K Viktoria SteinAnita Rieder
May 5, 2007·Heart Failure Reviews·Paul J Hauptman
Jan 19, 2008·Journal of Behavioral Medicine·Karen S Ingersoll, Jessye Cohen
Oct 21, 2006·Journal of Pharmacokinetics and Pharmacodynamics·Jun Li, Fahima Nekka
Jan 1, 2013·Journal of Pharmacokinetics and Pharmacodynamics·Pierre-Emmanuel Lévy Véhel, Jacques Lévy Véhel
Nov 7, 2002·Current Hypertension Reports·William C Gerth
Aug 4, 2006·Current Hypertension Reports·Giuseppe Mancia, Gianfranco Parati
Jun 21, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Keith C Ferdinand, Samar A Nasser
Nov 16, 2005·Journal of the American Medical Directors Association·Eric G Tangalos, Barbara J Zarowitz
Dec 2, 2006·Research in Social & Administrative Pharmacy : RSAP·Thomas R Einarson
Sep 27, 2003·Clinical Therapeutics·Anke RichterSusan L Dennett
Apr 24, 2013·Nature Reviews. Nephrology·Ramón C HermidaFrancesco Portaluppi
Sep 24, 2005·Journal of Human Hypertension·N B HassanA R A Rahman
Mar 3, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Charles FlexnerUNKNOWN ACTG A5073 Study Team
Dec 25, 2004·International Journal of Clinical Practice. Supplement·J Z Parra CarrilloM D C García Luna Viesca
Feb 7, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shivaani KummarJames H Doroshow
Nov 21, 2013·The Pan African Medical Journal·Méo Stéphane IkamaJean Louis Nkoua
Apr 19, 2007·BMC Health Services Research·Sandra van DulmenJozien Bensing
Jan 14, 2012·Circulation Journal : Official Journal of the Japanese Circulation Society·Masafumi KitakazeHiromu Nakajima
Jul 23, 2011·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Rebecca J StackPeter R Noyce
Jan 14, 2012·Vascular Health and Risk Management·John M Flack, Samar A Nasser
May 8, 2010·Vascular Health and Risk Management·Domenico GalzeranoCarlo Gaudio
Feb 8, 2005·PharmacoEconomics·Andrew M Peterson, William F McGhan
Mar 26, 2002·Clinical Therapeutics·Alan Lyles
Aug 4, 2012·Current Medical Research and Opinion·Michael S KostapanosDimitri P Mikhailidis
Jul 15, 2015·Research in Social & Administrative Pharmacy : RSAP·Vicki S ConnPam Cooper

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.